Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 74

1.

New immunosuppressants in pediatric solid organ transplantation.

Marks SD.

Curr Opin Organ Transplant. 2012 Oct;17(5):503-8. doi: 10.1097/MOT.0b013e32835741cd. Review.

PMID:
22890043
[PubMed - indexed for MEDLINE]
2.

Novel strategies in immunosuppression: issues in perspective.

Webber A, Hirose R, Vincenti F.

Transplantation. 2011 May 27;91(10):1057-64. doi: 10.1097/TP.0b013e3182145306. Review.

PMID:
21412186
[PubMed - indexed for MEDLINE]
3.

Recent advances in immunosuppressive therapy for prevention of renal allograft rejection.

Lunsford KE, Barbas AS, Brennan TV.

Curr Opin Organ Transplant. 2011 Aug;16(4):390-7. doi: 10.1097/MOT.0b013e328348b420. Review.

PMID:
21666473
[PubMed - indexed for MEDLINE]
4.

Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.

Swiatecka-Urban A.

Paediatr Drugs. 2003;5(10):699-716. Review.

PMID:
14510627
[PubMed - indexed for MEDLINE]
5.

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP.

Lancet. 1997 Oct 25;350(9086):1193-8. Erratum in: Lancet 1997 Nov 15;350(9089):1484.

PMID:
9652559
[PubMed - indexed for MEDLINE]
6.

Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview.

Höcker B, Tönshoff B.

Paediatr Drugs. 2009;11(6):381-96. doi: 10.2165/11316100-000000000-00000. Review.

PMID:
19877724
[PubMed - indexed for MEDLINE]
7.

Co-stimulation blockade as a new strategy in kidney transplantation: benefits and limits.

Snanoudj R, Zuber J, Legendre C.

Drugs. 2010 Nov 12;70(16):2121-31. doi: 10.2165/11538140-000000000-00000. Review.

PMID:
20964456
[PubMed - indexed for MEDLINE]
8.

Induction therapy in pediatric renal transplant recipients: an overview.

Moudgil A, Puliyanda D.

Paediatr Drugs. 2007;9(5):323-41. Review.

PMID:
17927304
[PubMed - indexed for MEDLINE]
9.

Prevention and treatment of renal allograft rejection: new therapeutic approaches and new insights into established therapies.

Lu CY, Sicher SC, Vazquez MA.

J Am Soc Nephrol. 1993 Dec;4(6):1239-56. Review.

PMID:
8130352
[PubMed - indexed for MEDLINE]
Free Article
10.

Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.

Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F; Phase III Daclizumab Study Group.

Transplantation. 2001 Sep 15;72(5):839-45.

PMID:
11571447
[PubMed - indexed for MEDLINE]
11.

Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.

Pretagostini R, Cinti P, Lai Q, Poli L, Berloco PB.

Transpl Immunol. 2008 Nov;20(1-2):3-5. doi: 10.1016/j.trim.2008.08.008. Epub 2008 Sep 4.

PMID:
18773959
[PubMed - indexed for MEDLINE]
12.

Immunosuppressive treatment options in renal transplantation.

Ciancio G, Burke GW, Jorge D, Rosen A, Miller J.

Minerva Urol Nefrol. 2005 Sep;57(3):141-9. Review.

PMID:
15986013
[PubMed - indexed for MEDLINE]
13.

Basiliximab: a review of its use as induction therapy in renal transplantation.

McKeage K, McCormack PL.

BioDrugs. 2010 Feb 1;24(1):55-76. doi: 10.2165/11203990-000000000-00000. Review.

PMID:
20055533
[PubMed - indexed for MEDLINE]
14.

Management of the kidney transplant recipient.

Padiyar A, Akoum FH, Hricik DE.

Prim Care. 2008 Sep;35(3):433-50, v. doi: 10.1016/j.pop.2008.03.003. Review.

PMID:
18710663
[PubMed - indexed for MEDLINE]
15.

Immunosuppression in the era of biological agents.

Grinyó JM, Cruzado JM, Bestard O, Vidal Castiñeira JR, Torras J.

Adv Exp Med Biol. 2012;741:60-72. doi: 10.1007/978-1-4614-2098-9_5.

PMID:
22457103
[PubMed - indexed for MEDLINE]
16.

Evolutionary experience with immunosuppression in pediatric intestinal transplantation.

Bond GJ, Mazariegos GV, Sindhi R, Abu-Elmagd KM, Reyes J.

J Pediatr Surg. 2005 Jan;40(1):274-9; discussion 279-80.

PMID:
15868597
[PubMed - indexed for MEDLINE]
17.

Steroid or calcineurin inhibitor-sparing immunosuppressive protocols.

Grinyó JM, Cruzado JM.

Contrib Nephrol. 2005;146:30-42. Review.

PMID:
15567918
[PubMed - indexed for MEDLINE]
18.

A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection.

Yuan X, Dong VM, Coito AJ, Waaga AM, Salama AD, Benjamin CD, Sayegh MH, Chandraker A.

Transplantation. 2002 Jun 15;73(11):1736-42.

PMID:
12084995
[PubMed - indexed for MEDLINE]
19.

Modulating T-cell costimulation as new immunosuppressive concept in organ transplantation.

Pilat N, Schwarz C, Wekerle T.

Curr Opin Organ Transplant. 2012 Aug;17(4):368-75. doi: 10.1097/MOT.0b013e328355fc94. Review.

PMID:
22790071
[PubMed - indexed for MEDLINE]
20.

Prevention of transplant rejection: current treatment guidelines and future developments.

Perico N, Remuzzi G.

Drugs. 1997 Oct;54(4):533-70. Review.

PMID:
9339960
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk